ACON | tickerfilter.com

Fundamental analysis

34%

Profitability 25%

Dept financing 17%

Liquidity 19%

Performance 50%

Company vs Stock growth

10.971 K 14.407 K

3.436 K 31.32%

0.208 0.170

-0.038 -18.32%

+ Add row to compare

Performance

5 Days

-25.88%

1 Month

573.95%

3 Months

6,737.17%

6 Months

4,493.36%

1 Year

2,512.38%

2 Year

-36.71%

Key data

Stock price

$8.02

P/E Ratio

0.00

DAY RANGE

$8.02 - $9.66

EPS

-$0.92

52 WEEK RANGE

$0.03 - $20.84

52 WEEK CHANGE

$2,512.38

MARKET CAP

1.579 M

YIELD

N/A

SHARES OUTSTANDING

8.611 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

03-28-2025

NEXT EARNINGS DATE

04-15-2025

BETA

-0.93

PUBLIC FLOAT

AVERAGE 10 VOLUME

$85,447

AVERAGE 30 VOLUME

$5,170,183

Company detail

CEO: Brent Ness
Region: US
Website: aclarion.com
Employees: 7
IPO year: 2022

Issue type: Common Stock
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services

Aclarion, Inc. develops software application for magnetic resonance spectroscopy (MRS) in the U.S. It offers NOCISCAN-LS Post-Processor suite, NOCICALC-LS, and NOCIGRAM-LS. The company was formerly known as Nocimed, which changed its name to ACLarion in December 2021.

ACON - Aclarion, Inc.